Victory Capital Management
BCAX

Victory Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Victory Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$299K Hold
10,070
– – ﹤0.01% 2168
2026
Q1 		$200K Hold
10,070
– – ﹤0.01% 2198
2025
Q4 		$169K Buy
10,070
+160
+2% +$2.73K ﹤0.01% 2225
2025
Q3 		$156K Hold
9,910
– – ﹤0.01% 2248
2025
Q2 		$92.1K Sell
9,910
-24,520
-71% -$292K ﹤0.01% 2334
2025
Q1 		$449K Buy
+34,430
New +$457K ﹤0.01% 2058

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Victory Capital Management's BCAX Position: Q2 2026 in Review

Victory Capital Management held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 10,070 shares worth $299K. The position accounts for ﹤0.01% of the portfolio, ranked #2168.

Victory Capital Management first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. The position peaked at $449K in Q1 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Victory Capital Management held 10,070 shares of Bicara Therapeutics worth $299K as of Q2 2026.
  • Victory Capital Management left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2168 holding.
  • Victory Capital Management first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Victory Capital Management's Bicara Therapeutics position peaked at $449K in Q1 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.